David Yang
Investment Team at Lux Capital
San Francisco Bay Area
Overview
Work Experience
Investment Team
2024 - Current
Lux Capital is an investment firm that invests in counter-conventional, seed-stage science and technology ventures.
Co-founder, Head of Ops & Strategy
2022 - 2024
Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients.
Raised $54,000,000.00 from The Children's Hospital of Philadelphia, Modi Ventures, 8VC, Gaingels, Samsung Life Science Fund, DCVC Bio and Ben Franklin Technology Partners.
Investment Team
2020 - 2024
Early-stage life sciences investments & incubations. Select portfolio: Photys Tx, Dren Bio, Latus Bio, Atomic AI (Board Observer), Unlearn AI (Board Observer), Tilda Research (Board Observer), Flywheel (Board Observer), Latent Labs (Board Observer), Portal Bio, Orchestra Bio Started the Bio-IT Fellowship to partner with entrepreneurial scientists: https://www.8vc.com/bio-it-fellowship
8VC transform the technology infrastructure behind many industries.
Research Associate
2017 - 2020
RNA targeting CRISPR systems for viral diagnostics and surveillance at the Pardis Sabeti lab * HC Metsky et al. Nature Biotechnology (2022) * DS Griesemer et al. Cell (2021) * CM Ackerman and C Myhrvold et al. Nature (2020) * DK Yang et al. Machine Learning in Computational Biology (2019) * HC Metsky and KJ Siddle et al. Nature Biotechnology (2019) https://scholar.google.com/citations?user=09tlyHEAAAAJ&hl